Drug intelligence / Profile preview

dequalinium chloride

Development stage
Unknown
Lead developer
MacroPhar
Modality
Small Molecules
Administration
Vaginal
01

Overview

Pregyn is an antiseptic vaginal tablet containing dequalinium chloride, developed and marketed by MacroPhar for the treatment of bacterial vaginosis (BV). Dequalinium chloride is a quaternary ammonium cation that functions as a broad-spectrum antimicrobial agent. It is effective against a wide range of Gram-positive and Gram-negative bacteria, as well as certain fungi and protozoa. The drug exerts its therapeutic effect by increasing the permeability of bacterial cell membranes and inhibiting vital enzymatic activities, which leads to the loss of cellular components and subsequent cell death. As a non-antibiotic treatment, it serves as an alternative to traditional therapies like metronidazole or clindamycin, particularly in regions where it is approved as an over-the-counter or prescription generic product.

Brand names
Pregyn
Other names
dequalinium
02

Targets

Muscle-type nicotinic acetylcholine receptorMPER (Human immunodeficiency virus type 1 envelope glycoprotein 41)ChiA (Chitinase A)SK channel (Small-conductance calcium-activated potassium channel)ATP SynthasePKC (Protein kinase C family)Neuraminidase

Beyond the preview

Go deeper on dequalinium chloride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dequalinium chloride.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call